J&J Earnings

• J&J expects COVID-19 vaccine sales boost in 2022 on strong demand

  Johnson & Johnson is expecting that sales of its COVID-19 vaccines could rise to $3.5 billion in 2022, though the total will not account for much of its overall profits.

  Economy

  Jan 25, 2022
  
• Johnson & Johnson eyes US$2.5B in COVID-19 vaccine sales despite Q3 slide

  Johnson & Johnson said it recorded US$766 million in sales of the shot in the first nine months of 2021, and would need sales to triple in the fourth quarter to meet its target.

  Money

  Oct 19, 2021
  
• Advertisement
• J&J expects to sell $2.5B in COVID-19 vaccines this year despite safety issues

  J&J expects to produce 500 million to 600 million doses of the vaccine this year, Chief Financial Officer Joseph Wolk said.

  Money

  Jul 21, 2021